Analysts expect that Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) will announce $867.33 million in sales for the current fiscal quarter, Zacks Investment Research reports. Nine analysts have issued estimates for Alexion Pharmaceuticals’ earnings. The highest sales estimate is $890.00 million and the lowest is $848.22 million. Alexion Pharmaceuticals reported sales of $798.52 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 8.6%. The company is expected to report its next earnings results on Thursday, October 26th.

According to Zacks, analysts expect that Alexion Pharmaceuticals will report full-year sales of $867.33 million for the current fiscal year, with estimates ranging from $3.42 billion to $3.60 billion. For the next year, analysts anticipate that the company will post sales of $4.05 billion per share, with estimates ranging from $3.92 billion to $4.27 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that cover Alexion Pharmaceuticals.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 EPS for the quarter, topping the consensus estimate of $1.08 by $0.48. The company had revenue of $912.00 million for the quarter, compared to analyst estimates of $846.15 million. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The business’s revenue was up 21.1% on a year-over-year basis. During the same period in the previous year, the firm earned $1.13 EPS.

A number of analysts have recently commented on ALXN shares. UBS AG restated a “buy” rating and issued a $142.00 price target (up from $140.00) on shares of Alexion Pharmaceuticals in a report on Monday, June 26th. Morgan Stanley restated an “overweight” rating and issued a $153.00 price objective (up previously from $141.00) on shares of Alexion Pharmaceuticals in a research note on Friday, July 28th. J P Morgan Chase & Co raised Alexion Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their target price for the company from $163.00 to $175.00 in a research report on Tuesday, September 5th. Leerink Swann reaffirmed an “outperform” rating and issued a $182.00 target price (up previously from $170.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, September 13th. They noted that the move was a valuation call. Finally, SunTrust Banks, Inc. reissued a “buy” rating and set a $180.00 price target (up previously from $170.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, September 13th. Five investment analysts have rated the stock with a hold rating, nineteen have given a buy rating and three have assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $157.21.

COPYRIGHT VIOLATION WARNING: “Alexion Pharmaceuticals, Inc. (ALXN) Expected to Announce Quarterly Sales of $867.33 Million” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another domain, it was copied illegally and republished in violation of United States and international copyright laws. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/09/28/alexion-pharmaceuticals-inc-alxn-expected-to-announce-quarterly-sales-of-867-33-million.html.

Alexion Pharmaceuticals (NASDAQ:ALXN) opened at 139.45 on Thursday. Alexion Pharmaceuticals has a 1-year low of $96.18 and a 1-year high of $149.34. The firm has a market cap of $31.12 billion, a P/E ratio of 60.47 and a beta of 1.40. The stock’s 50 day moving average price is $139.14 and its 200 day moving average price is $124.77.

In related news, Director Ann M. Veneman sold 700 shares of the firm’s stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $137.74, for a total value of $96,418.00. Following the sale, the director now owns 6,315 shares of the company’s stock, valued at $869,828.10. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Julie O’neill sold 11,160 shares of the firm’s stock in a transaction that occurred on Monday, August 28th. The shares were sold at an average price of $140.00, for a total transaction of $1,562,400.00. Following the completion of the sale, the executive vice president now directly owns 26,704 shares in the company, valued at approximately $3,738,560. The disclosure for this sale can be found here. In the last three months, insiders sold 17,070 shares of company stock valued at $2,416,869. Insiders own 4.35% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in ALXN. Guardian Life Insurance Co. of America grew its position in shares of Alexion Pharmaceuticals by 0.7% during the first quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 6 shares during the last quarter. Meeder Asset Management Inc. purchased a new stake in shares of Alexion Pharmaceuticals during the 1st quarter worth $111,000. Fiduciary Trust Co. purchased a new stake in shares of Alexion Pharmaceuticals during the 2nd quarter worth $111,000. Huntington National Bank boosted its position in shares of Alexion Pharmaceuticals by 1,084.6% during the 2nd quarter. Huntington National Bank now owns 1,078 shares of the biopharmaceutical company’s stock worth $131,000 after purchasing an additional 987 shares in the last quarter. Finally, Penserra Capital Management LLC boosted its position in shares of Alexion Pharmaceuticals by 13.0% during the 2nd quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock worth $151,000 after purchasing an additional 144 shares in the last quarter. 94.17% of the stock is currently owned by institutional investors.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Get a free copy of the Zacks research report on Alexion Pharmaceuticals (ALXN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.